文献速递预防保健、筛查与疫苗慢病管理

新冠疫苗对新冠后症状的有效性:瑞典589722人队列研究

Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study.
PubMed 文献 · BMJ · 2023-11-22

结果显示,接种任意剂次疫苗与PCC风险降低相关(调整后风险比0.42,95%CI 0.38-0.46),疫苗有效性为58%;按剂次分析,一剂、两剂和≥三剂的有效性分别为21%、59%和73%。结论提示感染前接种疫苗与降低PCC诊断风险强相关。

要点

  • 感染前接种新冠疫苗与PCC诊断风险降低相关,调整后风险比0.42(95%CI 0.38-0.46)。
  • 疫苗有效性随剂次增加而提高:一剂21%、两剂59%、≥三剂73%。
  • 研究支持基础接种新冠疫苗以减轻人群PCC负担。

核心结论

  • 感染前接种新冠疫苗与降低PCC临床诊断风险强相关,疫苗有效性为58%。

研究设计与样本

  • 随访至死亡、移民、接种疫苗、再感染、PCC诊断(ICD-10 U09.9)或随访结束(2022年11月30日),以先发生者为准。
  • 感染前至少接种一剂新冠疫苗者视为已接种,采用Cox回归调整年龄、性别、合并症、2019年医疗接触次数、社会经济因素及感染时优势病毒变异株。

主要发现

  • 接种任意剂次疫苗与PCC风险降低相关,调整后风险比0.42(95%CI 0.38-0.46),疫苗有效性58%。

关键数值与推荐

  • PCC主要结局定义为临床诊断PCC(ICD-10诊断代码U09.9)。
  • 疫苗有效性按感染前接种剂次分层:一剂21%、两剂59%、≥三剂73%。
  • 总体疫苗有效性58%,调整后风险比0.42(95%CI 0.38-0.46)。

临床怎么用

  • 全科医生可依据本研究结果向患者说明感染前接种新冠疫苗与降低PCC诊断风险相关。
  • 对符合接种条件者,可参考随剂次增加而提高的疫苗有效性(一剂21%、两剂59%、≥三剂73%)进行接种建议。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effectiveness of primary covid-19 vaccination (first two doses and first booster dose within the recommended schedule) against post-covid-19 condition (PCC). DESIGN: Population based cohort study. SETTING: Swedish Covid-19 Investigation for Future Insights-a Population Epidemiology Approach using Register Linkage (SCIFI-PEARL) project, a register based cohort study in Sweden. PARTICIPANTS: All adults (≥18 years) with covid-19 first registered between 27 December 2020 and 9 February 2022 (n=589 722) in the two largest regions of Sweden. Individuals were followed from a first infection until death, emigration, vaccination, reinfection, a PCC diagnosis (ICD-10 diagnosis code U09.9), or end of follow-up (30 November 2022), whichever came first. Individuals who had received at least one dose of a covid-19 vaccine before infection were considered vaccinated. MAIN OUTCOME MEASURE: The primary outcome was a clinical diagnosis of PCC. Vaccine effectiveness against PCC was estimated using Cox regressions adjusted for age, sex, comorbidities (diabetes and cardiovascular, respiratory, and psychiatric disease), number of healthcare contacts during 2019, socioeconomic factors, and dominant virus variant at time of infection. RESULTS: Of 299 692 vaccinated individuals with covid-19, 1201 (0.4%) had a diagnosis of PCC during follow-up, compared with 4118 (1.4%) of 290 030 unvaccinated individuals. Covid-19 vaccination with any number of doses before infection was associated with a reduced risk of PCC (adjusted hazard ratio 0.42, 95% confidence interval 0.38 to 0.46), with a vaccine effectiveness of 58%. Of the vaccinated individuals, 21 111 received one dose only, 205 650 received two doses, and 72 931 received three or more doses. Vaccine effectiveness against PCC for one dose, two doses, and three or more doses was 21%, 59%, and 73%, respectively. CONCLUSIONS: The results of this study suggest a strong association between covid-19 vaccination before infection and reduced risk of receiving a diagnosis of PCC. The findings highlight the importance of primary vaccination against covid-19 to reduce the population burden of PCC.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Lundberg-Morris L, Leach S, Xu Y, et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ. 2023. PMID: 37993131. doi:10.1136/bmj-2023-076990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。